RHYTHM PHARMACEUTICALS, INC. 8-K

What Happened

• Rhythm Pharmaceuticals (RYTM) announced on June 13, 2026 that it released a press release and presentation reporting interim six‑month data from its exploratory Phase 2 trial of setmelanotide in patients with Prader‑Willi syndrome (PWS). On June 15, 2026 the company issued an additional press release summarizing multiple new data presentations delivered at the Endocrine Society’s Annual Meeting (ENDO 2026) in Chicago. The June 13 presentation is available on Rhythm’s investor site.

Key Details

• Dates: press release and presentation published June 13, 2026; additional press release June 15, 2026 (ENDO 2026).
• Data: interim six‑month results from an exploratory Phase 2 clinical trial of setmelanotide in PWS were announced (trial and data summarized in the released presentation).
• Conference: multiple new data presentations were delivered at ENDO 2026 in Chicago and summarized in the June 15 release.
• Materials: the press releases and presentation were furnished as exhibits to the company’s Form 8‑K and the presentation is posted in the “Events and Presentations” section of ir.rhythmtx.com.

Why It Matters

• These disclosures update investors on clinical progress for setmelanotide in a rare obesity disorder (PWS). Interim Phase 2 data and presentations at a major scientific meeting can increase visibility among clinicians and investors and serve as development milestones to monitor as Rhythm advances its program.